Image via Yahoo Finance
Last updated
Gilead Sciences: Ma Activity
Gilead Sciences acquires Tubulis GmbH for $3.15B to expand oncology portfolio
Source: Yahoo Finance
The leadership read
Consolidation shifts the leadership question from growth to integration. For Gilead Sciences in Biotech & Pharma, the demand moves toward transformation and integration leaders who can merge teams, systems and cultures without losing momentum. Across Americas, watch whether the integration is properly resourced; deals are won or lost the year after they close.
Market context: The wider read — a Talent Market Index of 104.6 (Hot), down 1.9 month-on-month — shows Americas signal flow rising (+2.1pts).
Gilead Sciences: 1 signal in the last 90 days — in line with the Biotech & Pharma median of 1 across 24 tracked companies; 0.2% of MitchelLake's Asia signal flow; 3 tracked across 62 days.
MitchelLake in this thematic
Also at Gilead Sciences →
More signals across Biotech & Pharma
Ma Activity · Americas
Bristol Myers Squibb →Bristol Myers Squibb is in merger talks with AstraZeneca regarding a potential $400 billion megadeal
Ma Activity · Americas
Biogen →Biogen is relying on drugs acquired through the Apellis deal to offset weak sales of Leqembi (Alzheimer's drug), indicating strategic dependence on M&A to bolster pipeline performance.
Ma Activity · Americas
Bora Pharmaceuticals →Bora Group announced acquisition of MacroGenics' GMP manufacturing operations and CDMO business for US$122.5 million plus up to US$5 million contingent consideration. Includes biologics manufacturing facility in Rockville, Maryland with substantial backlog.
Leadership Change · Americas
Flagship Pioneering →Flagship Pioneering, a scientific innovation engine, appointed two Executive Partners: Fidah Alsagoff (Head of Global Initiatives) and Maggie Sahlman (Head of Fundraising and Investor Relations).
Capital Raising · Americas
Ratio Therapeutics →Ratio Therapeutics closed a Series C funding round of $70M for radiopharmaceutical trials, led by existing investors Duquesne Family Office and Bristol Myers Squibb, with new investor participation.
Leadership Change · Americas
Teva Pharmaceuticals →Teva Pharmaceuticals CEO Richard Francis discusses Q2 earnings, drug pipeline, and the company's direct listing on NYSE. Signals leadership visibility and capital market transition.
Intelligence powered by Autonodal ↗